Quantification of parasite burden of Trypanosoma cruzi and identification of Discrete Typing Units (DTUs) in blood samples of Latin American immigrants residing in Barcelona, Spain

Autor(es)

Tavares de Oliveira, Maykon ^{[1, 2]} ; Sulleiro, Elena ^[3] ; Silgado Gimenez, Aroa ^[3] ; de Lana, Marta ^{[4, 5]} ; Zingales, Bianca ^[6] ; Santana da Silva, Joao ^[7] ; Antonio Marin-Neto, J. ^[1] ; Molina, Israel ^[2]

Afiliação do(s) autor(es)

^[1] Univ Sao Paulo, Dept Internal Med, Cardiol Div, Med Sch Ribeirao Preto, FMRP, USP, Ribeirao Preto, SP - Brazil

^[2] Univ Autonoma Barcelona, Vall dHebron Univ Hosp, PROSICS, Dept Infect Dis, Barcelona - Spain

^[3] Univ Autonoma Barcelona, Vall dHebron Univ Hosp, Dept Microbiol, PROSICS, Barcelona - Spain

^[4] Fed Univ Ouro Preto UFOP, Sch Pharm, Ouro Preto, MG - Brazil

^[5] Fed Univ Ouro Preto UFOP, Ctr Res Biol Sci NUPEB, Ouro Preto, MG - Brazil

^[6] Univ Sao Paulo, Inst Chem, Dept Biochem, Sao Paulo, SP - Brazil

^[7] Univ Sao Paulo, Dept Biochem & Immunol, Ribeirao Preto Med Sch, FMRP, USP, Ribeirao Preto, SP - Brazil

• Tipo de documento: Artigo Científico
• Fonte: PLoS Neglected Tropical Diseases; v. 14, n. 6 JUN 2020.
• Citações Web of Science: 3

Resumo

BackgroundTrypanosoma cruzi has a high genetic and biological diversity and has been subdivided into seven genetic lineages, named TcI-TcVI and TcBat. DTUs TcI-TcII-TcV and TcVI are agents of ChD in different regions of Latin America. Due to population movements, the disease is an emergent global public health problem. Thus, the aim of this study was to quantify the parasitic load and identify the presence of T. cruzi DTUs in 101 Latin American immigrants with chronic ChD, residing in Barcelona, Spain. Methodology / Principal findings 5ml of peripheral blood were collected in guanidine/EDTA from each patient for DNA extraction, quantification of the parasitic load and genotyping. A great variation of the parasitic load of the patients was verified: from 0.001 to 22.2 T. cruzi DNA (fg) / Blood DNA (ng). In patients from Bolivia the parasitic load was 3.764.43 T. cruzi DNA (fg) / Blood DNA (ng) (mean SD), in patients of other countries was 0.95 +/- 1.38 T. cruzi DNA (fg) / Blood DNA (ng). No statistically significant difference was observed in the parasitic load between patients with the indeterminate and cardiac forms of ChD (p = 0,57). Parasite genotyping was performed by multilocus conventional PCR. In patients from Bolivia there was a nearly equal prevalence of DTUs TcV (27/77), TcII/TcV/TcVI (26/77), and TcII/TcVI (22/77). TcVI was detected in only 2 samples (2/77). A higher prevalence of TcII/TcVI (19/24) was verified in patients of other countries, with low prevalence of TcII/TcV/TcVI (4/24) and TcV (1/24). Conclusions/Significance In this study, low/medium parasitic load was found in all patients evaluated. Our data corroborate previous conclusions indicating that patients from the Bolivia, living in Spain, are predominantly infected by TcV, and TcVI DTUs. On the other hand, in Non-Bolivians patients TcII/TcVI predominated. Surprisingly, in our cohort of 101 patients no infection by TcI DTU was observed. Author summaryTrypanosoma cruzi is divided in seven distinct genetic groups (TcI-TcVI) and TcBat. They can be related to several biological parameters, the main being resistance to specific treatment. Due to the intense migration movements, ChD has become a serious public health problem in Europe. Thus, the work has the important function of identifying the genetic variability of T. cruzi circulating in the European continent, in addition to assessing the parasitic burden present in 101 chronic chagasic patients, residing in Barcelona, Spain. We show differences in the predominance between the infecting DTUs among Bolivian (TcV) and non-Bolivian patients (TcII/TcVI). This is the first study to describe the presence of TcVI genotype in Europe. Although the level of parasite burden is low/medium, it is higher in patients from Bolivia when compared with patients of other countries. The low parasitic burden is a limitation factor for studies aimed at evaluating by qPCR the effects of treating this disease with the drugs available to date, Benznidazole and Nifurtimox, and for clinical trials of new drugs. The information generated in this study should impact planning of more effective public health interventions to improve the health of chagasic patients, control vertical transmission and treatment of ChD. (AU)

• Processo FAPESP: 16/25403-9 - Investigações sobre etiopatogenia, fisiopatologia e terapêutica em humanos e em modelo experimental com a cardiomiopatia da Doença de Chagas
• Beneficiário: José Antonio Marin-Neto
• Modalidade de apoio: Auxílio à Pesquisa - Temático
• Processo FAPESP: 19/11943-0 - Genotipagem de T. cruzi em amostras de pacientes imigrantes, residentes na Europa: correlação entre a epidemiologia molecular do Trypanosoma cruzi, com as diferentes formas clínicas da Doença de Chagas no continente europeu
• Beneficiário: Maykon Tavares de Oliveira
• Modalidade de apoio: Bolsas no Exterior - Estágio de Pesquisa - Pós-Doutorado